Intestinal toxicity induced by 5-fluorouracil in pigs: A new preclinical model

Chemotherapy

Volumn 53, Issue 5, 2007, Pages 344-355

  Manzano, M ^a   Bueno, P ^a   Rueda, R ^a   Ramirez Tortosa, C L ^b   Prieto, P A ^c   Lopez Pedrosa, J M ^a  

^a ABBOTT LABORATORIES   (Spain)

^b Jaén Medical Center   (Spain)

^c ABBOTT LABORATORIES   (United States)

Author keywords

5 Fluorouracil; 5 FU, intestinal toxicity; 5 FU induced mucositis, pigs

Indexed keywords

ALKALINE PHOSPHATASE; DISACCHARIDASE; FLUOROURACIL; GLUCOSE; GLUTATHIONE; LACTASE; SUCRASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELL DEATH; CELL PROLIFERATION; CHEMICAL ANALYSIS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; ENZYME ACTIVITY; GASTROINTESTINAL TOXICITY; HELPER CELL; INTESTINE INJURY; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; SMALL INTESTINE; SWINE;

ANIMALS; BODY WEIGHT; CELL SHAPE; DRUG EVALUATION, PRECLINICAL; FLUOROURACIL; GLUTATHIONE; INTESTINAL MUCOSA; INTESTINES; MICROSCOPY, ELECTRON, TRANSMISSION; MODELS, ANIMAL; OXIDATION-REDUCTION; SWINE;

EID: 34548687206     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107724     Document Type: Article

References (78)

1. Grem JL: 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 2000;18:299-313.
2. Peters GJ: Relative role of 5-fluorouracil activation and inactivation pathways on its cytotoxic effects; in Rustum YM (ed): Fluoropyrimidines in Cancer Therapy. Totowa, Humana Press, 2003, pp 1-27.
3. Ishitsuka H: Discovery and preclinical pharmacology of capecitabine; in Rustum YM (ed): Fluoropyrimidines in Cancer Therapy. Totowa, Humana Press, 2003, pp 249-259.
4. Potten CS: The role of stem cells in the regeneration of intestinal crypts after cytotoxic exposure; in Butterworth BE (ed): Chemically Induced Cell Proliferation: Implications for Risk Assessment. New York, Wiley-Liss, 1991, pp 155-171.
5. Bagrij T, Kralovanszky J, Gyeeryay F, Kiss E, Peters GJ: Influence of uridine treatment in mice on the protection of gastrointestinal toxicity caused by 5-FU. Anticancer Res 1993;13:789-793.
6. Inomata A, Horii I, Katsushi S: 5-Fluorouracil-induced intestinal toxicity: what determines the severity of damage to murine intestinal crypt epithelia? Toxicol Lett 2002;133:231-240.
7. Itoh N, Nishimura H, Matsuguchi T, Yajima T, Mokuno Y, Hiromatsu T, Nimura Y, Yoshikai Y: CD8a-deficient mice are highly susceptible to 5-fluorouracil-induced lethality. Clin Diagn Lab Immunol 2002;9:550-557.
8. Korenaga D, Honda M, Yasuda M, Inutsuka S, Nozoe T, Tashiro H: Increased intestinal permeability correlates with gastrointestinal toxicity among formulations of the fluorouracil analogue tegafur in rats. Eur Surg Res 2002;34:351-356.
9. Houghton JA, Houghton PJ, Wooten RS: Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2-deoxyuridine. Cancer Res 1979;39:2406-2413.
10. Mascia L, Ipata PL: Activation pathways of 5-fluorouracil in rat organs and in PC12 cells. Biochem Pharmacol 2001;62:213-218.
11. Lu ZH, Zhang R, Diasio RB: Comparison of dihydropyrimidine dehydrogenase form human, rat, pig and cow liver. Biochem Pharmacol 1993;46:945-952.
12. Egorova VV, Egorova GG, Lasarenko LV, Timofeeva NM, Sherbakov GG: Topography of digestive enzymes in the pigs small intestine at the early stages of ontogeny in the norm and pathology; in Lindberg JE, Ogle B (eds): Digestive Physiology of Pigs. New York, CABI Publishing, 2001, pp 49-51.
13. Miller ER, Ullrey DE: The pig as a model for human nutrition. Annu Rev Nutr 1987;7:361-382.
14. Dondelinger RF, Ghysels MP, Brisbois D, Donkers E, Snaps FR, Saunders J, Deviere J: Relevant radiological anatomy of the pigs as a training model in interventional radiology. Eur Radiol 1998;8:1254-1273.
15. Shulman RJ, Henning SJ, Nichols BL: The miniature pigs as a model for the study of intestinal enzyme development. Pediatr Res 1998;23:311-315.
16. Rothkötter HJ, Kirchhoff T, Pabst R: Lymphocyte and non-lymphoid cells in the epithelium and lamina propria of intestinal mucosa of pigs. Gut 1994;35:1582-1589.
17. Rothkötter HJ, Ulbrich H, Pabst R: The postnatal development of gut lamina propia lymphocytes: number, proliferation, and T- and B-cell subsets in conventional and germ-free pigs. Pediatr Res 1991;29:237-242.
18. Leschelle X, Robert V, Delpal S, Mouille B, Mayeur C, Martel P, Blachier F: Isolation of pig colonic crypts for cytotoxic assay of luminal compounds: effects of hydrogen sulphide, ammonia and deoxycholic acid. Cell Biol Toxicol 2002;18:193-203.
19. Gardner N, Haresign W, Spiller R, Farraj N, Wiseman J, Norbury H, Illum L: Development and validation of a pigs model for colon specific drug delivery. J Pharm Pharmacol 1996;48:689-693.
20. Simon AR, Warrens AN, Yazzie NP, Seebach JD, Sachs DH, Sykes M: Cross-species interactions of porcine and human integrins with their respective ligands: implications for xenogeneic tolerance induction. Transplantation 1998;66:385-394.
21. Verburg M, Renes IB, Meier HP, Taminiau JA, Buller HA, Einerhand AW, Dekker J: Selective sparing of goblet cells and paneth cells in the intestine of methotrexate-treated rats. Am J Physiol 2000;279:G1037-G1047.
22. Fata F, Ron IG, Kemeny N, O'Reilly E, Klimstra D, Kelsen DP: 5-Fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. Cancer 1999;86:1129-1134.
23. Aw TY: Cellular redox: a modulator of intestinal epithelial cell proliferation. News Physiol Sci 2003;18:201-203.
24. Subcommittee on Swine Nutrition/Committee on Animal Nutrition, Board of Agriculture, National Research Council: Nutrient Requirements of Swine, ed 10 rev. Washington, National Academy Press, 1998.
25. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
26. Labarca C, Paigen K: A simple, rapid and sensitive DNA assay procedure. Anal Biochem 1980;102:344-354.
27. Dahlqvist A: Assay of intestinal disaccharidases. Anal Biochem 1968;22:99-107.
28. Goldstein R, Klein T, Freier S, Menczel J: Alkaline phosphatase and disaccharidase activities in the rat intestine from birth to weaning. Effect of diet on enzyme development. Am J Clin Nutr 1970;24:1224-1231.
29. Carlberg I, Mannervik B: Glutathione reductase. Methods Enzymol 1985;113:485-495.
30. Flohé L, Günzler WA: Assays for glutathione peroxidase. Methods Enzymol 1985;105:209-221.
31. Anderson ME: Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol 1985;113:548-559.
32. Gautreaux M, Deitch E, Berg R: T lymphocytes in host defense against bacterial translocation from the gastrointestinal tract. Infect Immun 1994;62:2874-2884.
33. Reynolds ES: The use of lead citrate at high pH as an electron-opaque stain in electron microscopy. J Cell Biol 1963;17:208-212.
34. Zafiriou G, Grekou A, Stravoravdi P, Natsis K, Barich A: Histological and ultrastructural study of the effect of chemotherapy with 5-fluorouracil on normal liver of Wistar rats. Chemotherapy 2002;48:298-302.
35. Roche AC, Bognel JC, Bernier JJ: Correlation between the histological changes and glucose intestinal absorption following a single dose of fluorouracil. Digestion 1970;3:195-212.
36. Gardner ML, Samson RR, Heading RC: Changes in the absorptive and peptide hydrolase activities in rat small intestine after administration of 5-fluorouracil. Clin Sci Mol Med 1978;54:411-418.
37. De Roy van Zuidewijn DBW, Schillings PHM, Wobbes TH, et al: Morphometric analysis of the effects of antineoplastic drugs on mucosa of normal ileum and ileal anastomoses in rats. Exp Mol Pathol 1992;56:96-107.
38. Chevreau N, Wang YY, Funk-Archueta M: Effect of diets on 5-fluorouracil and cyclophosphamide toxicity. Nutr Cancer 1995;23:205-220.
39. Hirata K, Horie T: Changes in intestinal absorption of 5-fluorouracil-treated rats. Pharmacol Toxicol 1999;85:33-36.
40. Moore JV: Death of intestinal crypts and of their constituent cells after treatment by chemotherapeutic drugs. Br J Cancer 1984;49:25-32.
41. Pritchard DM, Potten CS, Hickman JA: The relationships between p53-dependent apoptosis, inhibition of proliferation, and 5-fluorouracil-induced histopathology in murine intestinal epithelia. Cancer Res 1998;588:5453-5465.
42. Huang FS, Kemp CJ, Williams JL, Erwin CR, Warner BW: Role of epidermal growth factor and its receptor in chemotherapy-induced intestinal injury. Am J Physiol 1992;282:G432-G442.
43. Yamazaki K, Yasuda N, Inoue T, Nagakura T, Kira K, Saeki T, Tanaka I: The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine. Eur J Pharmacol 2004;488:213-218.
44. Sonis ST, Tracey C, Shklar G, Jenson J, Florine D, Alameida C: An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Pathol 1990;69:437-443.
45. Clarke J, Butler R, Howarth G, Read L, Regester G: Exposure of oral mucosa to bioactive milk factors reduces severity of chemotherapy-induced mucositis in the hamster. Oral Oncol 2002;38:478-485.
46. 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 1990;253:387-394.
47. Kashfi K, McDougall CJ, Dannenberg AJ: Comparative effects of omeprazole on xenobiotic metabolizing enzymes in the rat and human. Clin Pharmacol Ther 1995;58:625-630.
48. Sobrero AF, Belvedere O: Relevance of scheduling to the efficacy of 5-fluorouracil alone and in combination with other agents; in Rustum YM (ed): Fluoropyrimidines in Cancer Therapy. Totowa, Humana Press, 2003, pp 129-138.
49. Almersjo OE, Gustavsson BG, Regardh CH, Wahlen P: Pharmacokinetic studies of 5-fluorouracil after oral and intravenous administration in man. Acta Pharmacol Toxicol 1980;46:329-336.
50. Andreyev HJN, Norman AR, Oates J, Cunningham D: Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignances? Eur J Cancer 1998;34:503-509.
51. Ross PJ, Ashely S, Norton A, Priest K, Waters JS, Eisen T, Smith IE, O'Brien MER: Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer 2004;90:1905-1911.
52. White RS, Fuqua WB, Barrett O Jr: The effect of 5-fluorouracil on small bowel mucosa. J Surg Oncol 1971;3:501-506.
53. Keefe DM, Gibson RJ, Hauer-Jensen M: Gastrointestinal mucositis. Semin Oncol Nurs 2004;20:38-37.
54. Melichar B, Dvorak J, Hyspler R, Zadak Z: Intestinal permeability in the assessment of intestinal toxicity of cytotoxic agents. Chemotherapy 2005;51:336-338.
55. Chen D, Wu G, Wang W, Wang J: Neutrophil infiltration is involved in 5-FU induced lipid peroxidative damage of the small intestine. Chin Med Sci J 1997;12:181-183.
56. Cunningham D, Morgan RJ, Mills PR, Nelson LM, Toner PG, Soukop M, McArdle CS, Russell RI: Functional and structural changes of the human proximal small intestine after cytotoxic therapy. J Clin Pathol 1985;38:265-270.
57. Wang TG, Gotoh Y, Jennings MH, Rhoads CA, Aw TY: Lipid hydroperoxide-induced apoptosis in human colonic CaCo-2 cells is associated with an early loss of cellular redox balance. FASEB J 2000;14:1567-1576.
58. Martensson J, Jain A, Meister A: Glutathione is required for intestinal function. Proc Natl Acad Sci USA 1990;87:1715-1719.
59. Durak I, Karaayvaz M, Kavutcu M, Cimen MY, Kacmaz M, Buyukkocak S, Ozturk HS: Reduced antioxidant defense capacity in myocardial tissue from guinea pigs treated with 5-fluorouracil. J Toxicol Environ Health A 2000;59:585-589.
60. Ijiri K, Potten CS: Further studies on the response of intestinal crypt cells of different hierarchical status to eighteen different cytotoxic agents. Br J Cancer 1987;55:113-123.
61. Potten CS, Wilson JW, Booth C: Regulation and significance of apoptosis in the stem cells of the gastrointestinal epithelium. Stem Cells 1997;15:82-93.
62. Merritt AJ, Potten CS, Kemp CJ, Hickman JA, Balmain A, Lane DP, Hall PA: The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res 1994;54:614-617.
63. Pritchard DM, Print C, O'Reilly L, Adams JM, Potten CS, Hickman JA: Bcl-w is an important determinant of damage-induced apoptosis in epithelia of small and large intestine. Oncogene 2000;19:3955-3959.
64. Bowen JM, Gibson RJ, Keefe DM, Cummins AG: Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology 2005;37:56-62.
65. Armstrong RD, Diasio RB: Metabolism and biological activity of 5′-deoxy-5-fluorouridine, a novel fluoropyrimidine. Cancer Res 1980;40:3333-3338.
66. Ohta Y, Sueki K, Kitta K, Takemoto K, Ishitsuka H, Yagi Y: Comparative studies on the immunosuppressive effect among 5′-deoxy-5-fluorouridine, ftorafur, and 5-fluorouracil. Gann 1980;71:190-196.
67. Kouchi Y, Maeda Y, Ohuchida A, Nomura N: Potassium oxonate modulation of 5-fluorouracil-induced myelotoxicity in murine and human colony forming assays of hematopoietic precursor cells. Toxicol Lett 2002;135:11-18.
68. Kimhi O, Drucker L, Neumann A, Shapiros H, Shapira J, Yarkoni S, Lahav M, Radnays J, Lishner M: Fluorouracil induces apoptosis and surface molecule modulation of peripheral blood leukocytes. Clin Lab Haematol 2004;26:327-333.
69. Kouchi Y, Maeda Y, Morinaga H, Ohuchida A: Immunotoxic effects of a new antineoplastic agent S-1 in mice - comparison with S-1, UFT and 5-FU. J Toxicol Sci 1996;213:691-701.
70. Kimura Y, Okuda H: Prevention by carp extract of myelotoxicity and gastrointestinal toxicity induced by 5-fluorouracil without loss of antitumor activity in mice. J Ethnopharmacol 1990;68:39-45.
71. Yeager AM, Levin J, Levin FC: The effects of 5-fluorouracil on hematopoiesis: studies of murine megakaryocyte-CFC, granulocytemacrophage-CFC, and peripheral blood cell levels. Exp Hematol 1983;11:944-952.
72. Tillman DM, Petak I, Houghton JA: A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells. Clin Cancer Res 1999;5:425-430.
73. Eichhorst ST, Muerkoster S, Weigand MA, Krammer PH: The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95(APO-1/Fas) system. Cancer Res 2001;61:243-248.
74. Adachi Y, Taketani S, Oyaizu H, Ikebukuro K, Tokunaga R, Ikehara S: Apoptosis of colorectal adenocarcinoma induced by 5-FU and/or IFN-γ through caspase 3 and caspase 8. Int J Oncol 1999;15:1191-1196.
75. Laurenz JC, Hadjisavas M, Chovanic GW, Bazer FW: Myelosuppression in the pig (Sus scrofa) : uteroferrin reduces the myelosuppressive effects of 5-fluorouracil in young pigs. Comp Biochem Physiol 1997;116:369-377.
76. 1 accelerates restoration of T-cell-mediated neutralizing antibody response in immunocompromised hosts. Int Immunopharmacol 2002;2:39-46.
77. Inagaki-Ohara K, Kobayashi N, Nishimura H, Sakai T, Matsumoto Y, Hiromatsu K, Awaya A, Yoshikai Y: Effects of a nonapeptide thymic hormone on intestinal intraepithelial lymphocytes in mice following administration of 5-fluorouracil. Cell Immunol 1996;171:30-40.
78. Outram SV, Varas A, Pepicelli CV, Crompton T: Hedgehog signaling regulates differentiation from double-negative to doublepositive thymocyte. Immunity 2000;13:187-189.